ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efanesoctocog alfa

Also written as “Efanesoctocog alfa”, “efanesoctocog alfa (BIVV001)” and “BIVV001 (Low Dose)”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 2 companies.

Drug pageEfanesoctocog alfa: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 16, 202512 company-led studies, 5 open or runningNext primary completion: Jan 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only72 open or runningphase 4since Apr 16, 2025Jun 29, 2017Jan 15, 2027phase 3 · NCT04644575
Swedish Orphan Biovitrum53 open or runningphase 4since Dec 18, 2024Mar 21, 2023Mar 2027phase 3 · NCT06716814

Also a collaborator on its studies: PSI CRO.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Swedish Orphan Biovitrum only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2019Named efanesoctocog alfaINNProposed as its International Nonproprietary Name in WHO's List 122
  2. Mar 21, 2023First study: phase 3 study in Hemophilia AFirst studyNCT05817812 · 93 enrolled · Austria, Croatia, Czechia and more
  3. Aug 28, 2024Phase 1 study in Hemophilia ANCT06579144 · 24 enrolled · Bulgaria, Germany, Italy and more
  4. Oct 2, 2024Phase 3 study in Hemophilia ANCT06716814 · 89 enrolled · Bulgaria, France, Greece and more
  5. Dec 18, 2024Phase 4 study in Hemophilia ANCT06752850 · 37 enrolled · Italy, Norway, Spain and more
  6. Apr 16, 2025Phase 4 study in Hemophilia ANCT06940830 · 252 enrolled · Croatia, Czechia, France and more

Ahead

  1. Nov 17, 2026Primary completion: phase 4 study in Hemophilia ANCT06752850
  2. Mar 2027Primary completion: phase 3 study in Hemophilia ANCT06716814
  3. Dec 2028Primary completion: phase 4 study in Hemophilia ANCT06940830

TargetBeta

F8 →read by rule
“A recombinant fusion protein comprising a single chain B-domain deleted (BDD) analog of human antihemophilic factor (coagulation factor VIII; FVIII) covalently ”NCIt, by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
antihemophilic factor, human recombinantruleTakedaphase 416
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

All 5 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06940830Hemophilia A · Croatia, Czechia, France and more4Active, not recruitingDec 2028252
NCT06752850Hemophilia A · Italy, Norway, Spain and more4Active, not recruitingNov 17, 202637
NCT06716814Hemophilia A · Bulgaria, France, Greece and more3Active, not recruitingMar 202789
NCT06579144Hemophilia A · Bulgaria, Germany, Italy and more1CompletedMay 21, 202624
NCT05817812Hemophilia A · Austria, Croatia, Czechia and more3CompletedJun 2, 202693

How it is read

Names in the registry

  • “Efanesoctocog alfa”, 7 entries
  • “efanesoctocog alfa (BIVV001)”, 4 entries
  • “BIVV001 (Low Dose)”, 1 entry
  • “BIVV001 (High Dose)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.